Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label, Parallel-group, Multicenter Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients With Wet Age-Related Macular Degeneration (AMD)
Conditions
Interventions
NT-101 Low Dose
NT-101 High Dose
Locations
4
United States
Elman Retina Group
Rosedale, Maryland, United States
Duke Eye Center
Durham, North Carolina, United States
Erie Retina Research
Erie, Pennsylvania, United States
Texas Retina Associates
Dallas, Texas, United States
Start Date
March 11, 2025
Primary Completion Date
December 15, 2025
Completion Date
May 1, 2026
Last Updated
April 8, 2026
NCT06668064
NCT06683742
NCT07255885
NCT06969001
NCT05562336
NCT01986907
Lead Sponsor
NexThera Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions